Global Anti-CD20 Monoclonal Antibodies (mABs) Market 2024-2028

The Anti-CD20 monoclonal antibodies (mABs) market is forecasted to grow by USD 11425.15 mn during 2023-2028, accelerating at a CAGR of 10.31% during the forecast period. The report on the Anti-CD20 monoclonal antibodies (mABs) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increased use of combination therapies, high target affinity and specificity of Anti-CD20 mABs, and strong pipeline and recent approvals.

Market Scope
Base Year	2023
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	9.85%
CAGR	10.31%
Incremental Value	$11425.15mn

Technavio's Anti-CD20 monoclonal antibodies (mABs) market is segmented as below:

By Product

Oncology
Neurology
Immunology

By Type

First generation Anti-CD20 monoclonal antibody
Second generation Anti-CD20 monoclonal antibody
Third generation Anti-CD20 monoclonal antibody

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the increasing awareness about therapeutic areas as one of the prime reasons driving the Anti-CD20 monoclonal antibodies (mABs) market growth during the next few years. Also, the presence of reimbursement and patient assistance programs and the development of cd20 bispecific antibodies will lead to sizable demand in the market.

The report on the Anti-CD20 monoclonal antibodies (mABs) market covers the following areas:

Anti-CD20 monoclonal antibodies (mABs) market sizing
Anti-CD20 monoclonal antibodies (mABs) market forecast
Anti-CD20 monoclonal antibodies (mABs) market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Anti-CD20 monoclonal antibodies (mABs) market vendors that include Acrotech Biopharma Inc., Amgen Inc., AstraZeneca Plc, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd.. Also, the Anti-CD20 monoclonal antibodies (mABs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR73017

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global anti-CD20 monoclonal antibodies (mABs) market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global anti-cd20 monoclonal antibodies (mabs) market 2018 - 2022 ($ million)
4.2 Product Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
4.3 Type Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

6.1 Market segments
Exhibit 30: Chart on Product - Market share 2023-2028 (%)
Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 Oncology - Market size and forecast 2023-2028
Exhibit 34: Chart on Oncology - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Oncology - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Oncology - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Oncology - Year-over-year growth 2023-2028 (%)
6.4 Neurology - Market size and forecast 2023-2028
Exhibit 38: Chart on Neurology - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Neurology - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Neurology - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Neurology - Year-over-year growth 2023-2028 (%)
6.5 Immunology - Market size and forecast 2023-2028
Exhibit 42: Chart on Immunology - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Immunology - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Immunology - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Immunology - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Product
Exhibit 46: Market opportunity by Product ($ million)
Exhibit 47: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Type

7.1 Market segments
Exhibit 48: Chart on Type - Market share 2023-2028 (%)
Exhibit 49: Data Table on Type - Market share 2023-2028 (%)
7.2 Comparison by Type
Exhibit 50: Chart on Comparison by Type
Exhibit 51: Data Table on Comparison by Type
7.3 First generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028
Exhibit 52: Chart on First generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on First generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on First generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on First generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
7.4 Second generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028
Exhibit 56: Chart on Second generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Second generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Second generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Second generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
7.5 Third generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028
Exhibit 60: Chart on Third generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Data Table on Third generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
Exhibit 62: Chart on Third generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Third generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Type
Exhibit 64: Market opportunity by Type ($ million)
Exhibit 65: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share by geography 2023-2028 (%)
Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Canada - Market size and forecast 2023-2028
Exhibit 91: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.9 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.10 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.11 China - Market size and forecast 2023-2028
Exhibit 103: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 104: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 105: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on China - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity by geography
Exhibit 107: Market opportunity by geography ($ million)
Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 Acrotech Biopharma Inc.
Exhibit 115: Acrotech Biopharma Inc. - Overview
Exhibit 116: Acrotech Biopharma Inc. - Product / Service
Exhibit 117: Acrotech Biopharma Inc. - Key offerings
12.4 Amgen Inc.
Exhibit 118: Amgen Inc. - Overview
Exhibit 119: Amgen Inc. - Product / Service
Exhibit 120: Amgen Inc. - Key offerings
12.5 AstraZeneca Plc
Exhibit 121: AstraZeneca Plc - Overview
Exhibit 122: AstraZeneca Plc - Product / Service
Exhibit 123: AstraZeneca Plc - Key news
Exhibit 124: AstraZeneca Plc - Key offerings
12.6 Celltrion Healthcare Co. Ltd.
Exhibit 125: Celltrion Healthcare Co. Ltd. - Overview
Exhibit 126: Celltrion Healthcare Co. Ltd. - Product / Service
Exhibit 127: Celltrion Healthcare Co. Ltd. - Key offerings
12.7 F. Hoffmann La Roche Ltd.
Exhibit 128: F. Hoffmann La Roche Ltd. - Overview
Exhibit 129: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 130: F. Hoffmann La Roche Ltd. - Key news
Exhibit 131: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 132: F. Hoffmann La Roche Ltd. - Segment focus
12.8 Fosun International Ltd.
Exhibit 133: Fosun International Ltd. - Overview
Exhibit 134: Fosun International Ltd. - Product / Service
Exhibit 135: Fosun International Ltd. - Key offerings
12.9 Genmab AS
Exhibit 136: Genmab AS - Overview
Exhibit 137: Genmab AS - Key offerings
12.10 IGM Biosciences Inc.
Exhibit 138: IGM Biosciences Inc. - Overview
Exhibit 139: IGM Biosciences Inc. - Product / Service
Exhibit 140: IGM Biosciences Inc. - Key offerings
12.11 JSC BIOCAD
Exhibit 141: JSC BIOCAD - Overview
Exhibit 142: JSC BIOCAD - Product / Service
Exhibit 143: JSC BIOCAD - Key offerings
12.12 LFB SA
Exhibit 144: LFB SA - Overview
Exhibit 145: LFB SA - Product / Service
Exhibit 146: LFB SA - Key offerings
12.13 Novartis AG
Exhibit 147: Novartis AG - Overview
Exhibit 148: Novartis AG - Business segments
Exhibit 149: Novartis AG - Key offerings
Exhibit 150: Novartis AG - Segment focus
12.14 Pfizer Inc.
Exhibit 151: Pfizer Inc. - Overview
Exhibit 152: Pfizer Inc. - Product / Service
Exhibit 153: Pfizer Inc. - Key news
Exhibit 154: Pfizer Inc. - Key offerings
12.15 Regeneron Pharmaceuticals Inc.
Exhibit 155: Regeneron Pharmaceuticals Inc. - Overview
Exhibit 156: Regeneron Pharmaceuticals Inc. - Product / Service
Exhibit 157: Regeneron Pharmaceuticals Inc. - Key offerings
12.16 Spectrum Pharmaceuticals Inc.
Exhibit 158: Spectrum Pharmaceuticals Inc. - Overview
Exhibit 159: Spectrum Pharmaceuticals Inc. - Product / Service
Exhibit 160: Spectrum Pharmaceuticals Inc. - Key offerings
12.17 TG Therapeutics Inc.
Exhibit 161: TG Therapeutics Inc. - Overview
Exhibit 162: TG Therapeutics Inc. - Product / Service
Exhibit 163: TG Therapeutics Inc. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 164: Inclusions checklist
Exhibit 165: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 166: Currency conversion rates for US$
13.4 Research methodology
Exhibit 167: Research methodology
Exhibit 168: Validation techniques employed for market sizing
Exhibit 169: Information sources
13.5 List of abbreviations
Exhibit 170: List of abbreviations